Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of EBITDA Margin data on record, last reported at 186.78% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 48880.0% year-over-year to 186.78%; the TTM value through Dec 2025 reached 292.09%, up 337.0%, while the annual FY2025 figure was 292.09%, 337.0% up from the prior year.
  • EBITDA Margin reached 186.78% in Q4 2025 per CCCC's latest filing, up from 284.92% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 81.07% in Q4 2021 and bottomed at 1322.3% in Q2 2023.
  • Average EBITDA Margin over 5 years is 496.34%, with a median of 327.6% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: tumbled -117727bps in 2022, then surged 117424bps in 2024.
  • A 5-year view of EBITDA Margin shows it stood at 81.07% in 2021, then plummeted by -1452bps to 1258.34% in 2022, then grew by 17bps to 1041.92% in 2023, then soared by 35bps to 675.58% in 2024, then surged by 72bps to 186.78% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 186.78% in Q4 2025, 284.92% in Q3 2025, and 403.73% in Q2 2025.